Biopharma stocks have been among the worst performers in the bear market.
The SPDR S&P Biotech ETF lost more than half its value from early November to mid-June, while the NASDAQ Biotechnology Index dropped nearly 40 percent from August 2021 to mid-June.
Both benchmarks, however, have rebounded sharply in the past two weeks, jumping 22 percent and 17 percent, respectively.
